HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors

This publication has 122 references indexed in Scilit:

• The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2
  Nature Clinical Practice Oncology, 2008
• Expression of p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 Therapies in Breast Cancer
  JNCI Journal of the National Cancer Institute, 2007
• Neoadjuvant Therapy with Paclitaxel followed by 5-Fluorouracil, Epirubicin, and Cyclophosphamide Chemotherapy and Concurrent Trastuzumab in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: An Update of the Initial Randomized Study Population and Data of Additional Patients Treated with the Same Regimen
  Clinical Cancer Research, 2007
• Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial
  British Journal of Cancer, 2006
• A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer
  Proceedings of the National Academy of Sciences, 2006
• Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial
  Annals of Oncology, 2005
• PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
  Cancer Cell, 2004
• Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
  Nature Reviews Drug Discovery, 2004
• ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling
  The EMBO Journal, 1997
• Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene
  Science, 1987